Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Nature Communications Année : 2021

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

Résumé

Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.

Domaines

Neurobiologie
Fichier principal
Vignette du fichier
s41467-021-24319-x.pdf (15.2 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03647580 , version 1 (20-04-2022)

Licence

Paternité

Identifiants

Citer

Alberto Lleó, Henrik Zetterberg, Jordi Pegueroles, Thomas Karikari, María Carmona-Iragui, et al.. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome. Nature Communications, 2021, 12 (1), pp.4304. ⟨10.1038/s41467-021-24319-x⟩. ⟨hal-03647580⟩
28 Consultations
41 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More